HCG dosing — approved use and the TRT-adjunct pattern

HCG binds the LH/hCG receptor and drives gonadal steroidogenesis. Its distinguishing pharmacological feature versus native LH is duration: the molecule's heavily glycosylated beta subunit slows renal clearance, giving it a far longer effective half-life than the LH pulse it imitates. That is precisely what makes it useful as a single-injection ovulation trigger — one dose produces a sustained surge — and precisely what makes it accumulate if given repeatedly without regard to that persistence.

Approved labeling reflects this by making the dosing pattern, not just the amount, indication-specific.

The most instructive feature of that labeling is the size gap between indications. The single dose used to trigger ovulation is roughly an order of magnitude larger than the individual doses in a male hypogonadism course — and the label notes that a specific figure is recommended in the labeling for the gonadotropins used beforehand, meaning the trigger dose is coordinated with a different drug's protocol. A number lifted from one indication is not transferable to another.

HCG is quantified by biological activity — USP units, functionally interchangeable with international units — rather than by mass. Two consequences follow.

• Milligram arithmetic from other peptides does not apply. There is no meaningful "mg per vial" conversion to reason from.
• The product is supplied as a lyophilized powder plus a separate solvent, so the concentration in the syringe is set by how much diluent is added. The same vial can be reconstituted to very different strengths; the unit count per injection, not the volume, is the quantity that matters.

Assay variability compounds the point. Commercial hCG immunoassays have shown up to 50-fold differences in results between platforms (StatPearls, Human Chorionic Gonadotropin) — a reminder that hCG quantification is standardized only inside a regulated supply chain.

Use alongside testosterone therapy, to maintain intratesticular testosterone and testicular volume, is the most-discussed application and appears on no label. The clinical literature describes low-dose hCG given with exogenous testosterone as one of the strategies used to protect the testis during testosterone replacement, alongside selective estrogen receptor modulators (PMID 26813847). Community discussion converges on small doses given two to three times weekly by subcutaneous injection, but these are commonly cited figures rather than a validated standard, and they vary widely between sources.

Where the evidence is firmer is what hCG is up against. In men with pathological gonadotropin deficiency, pooled data across 41 studies and 1,673 patients show combined hCG plus FSH outperforming hCG alone on every sperm threshold measured, despite similar effects on serum testosterone and testicular volume (PMID 39445789). hCG alone restores the LH arm of the signal; it does not replace the FSH arm.

The label conditions safe ovulation induction on regular serum estradiol and transvaginal ultrasound monitoring, and restricts use with gonadotropin therapy to physicians experienced in infertility with access to monitoring facilities. On the male side, the aromatization that produces gynecomastia and edema is invisible without hormone panels. In both cases the dose is only half of the prescription — the other half is the monitoring that tells a clinician whether to change it. That is why even widely repeated off-label figures belong inside a prescriber's plan rather than copied from a forum post.